Material in a supply chain is tracked by a method of applying a DNA taggant set to a first batch of the material produced by a first supplier of the material. The DNA taggant set corresponds to a tag string corresponding to the first supplier. The first batch is aggregated with a second batch to create an aggregated lot. A sample is selected from the aggregated lot and tested to determine a DNA taggant set of the sample. After selecting a sample from the aggregated lot, the sample may be labeled with a grade and then placed in a receptacle corresponding to the grade.

Provided is a method including obtaining a corpus and an associated set of domain indicators. The method includes learning a set of vectors in an embedding space based on n-grams of the corpus. The method includes updating ontology graphs comprising a set of vertices and edges associating the set of vertices with each other. The method also includes determining a vector cluster using hierarchical clustering based on distances of the set of vectors with respect to each other in the embedding space and determining a hierarchy of the ontology graphs based on a set of domain indicators of a respective set of vertices corresponding to vectors of the vector cluster. The method also includes updating an index based on the ontology graphs.

Systems and methods are provided for identifying characteristics of a subject using a biofield scan obtained from the subject. An embodiment can include a method for cross-correlating biofield scans to an enome database, and/or a genome database. A phenotype history and a biofield scan can be created from a user. A user's biofield scan can be created from measured amplitude and frequency. A database is created from a user's phenotype history, and biofield scan. The user's phenotype history and biofield scans are then correlated with known physical and biochemical characteristics. A biofield signature is created and compared to the user's phenotype history, and biofield scan.

Systems and methods are provided for identifying characteristics of a subject using a biofield scan obtained from the subject. An embodiment can include a method for cross-correlating biofield scans to an enome database, and/or a genome database. A phenotype history and a biofield scan can be created from a user. A user's biofield scan can be created from measured amplitude and frequency. A database is created from a user's phenotype history, and biofield scan. The user's phenotype history and biofield scans are then correlated with known physical and biochemical characteristics. A biofield signature is created and compared to the user's phenotype history, and biofield scan.

The invention provides compounds for use as medicaments, which act by inhibiting CYP17A1 and CYP19A1 enzymes. The compounds have particular application in the treatment of cancer especially prostate cancer and breast cancer. The compounds have the formula: [Chem. 1] wherein: R is independently selected from the group consisting of optionally substituted arylamide; optionally substituted alkylarylamide; optionally substituted aryl carboxamide; optionally substituted cyanopiperidine; optionally substituted oxopiperidine; optionally substituted N-(pyridin-3-yl); optionally substituted pyridin-3-yl; optionally substituted pyrazole-4-carboxamide; optionally substituted pyrimidin-4-ylcarboxamide; optionally substituted pyrimidin-4-ylcarboxamide; optionally substituted 1H-pyrrol-2-ylcarboxamide; optionally substituted morpholin carboxamide; optionally substituted 1H-indazol-3-ylcarboxamide; optionally substituted 5-cyanopiperidin-3-ylcarboxamide; optionally substituted quinolin-7-yl; optionally substituted pyrazin-2-ylcarboxamide; optionally substituted 1H-1,3-benzodiazole-6-carboxamide; and optionally substituted 3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-ylcarboxamide; Each R1, R2, R3, R4, R5 is independently selected from the group consisting of H; OH; a halogen atom; OCH.sub.3; and NH.sub.2; and X is independently selected from the group consisting of O, H and OH. Some of the compounds are claimed per se and the invention also encompasses pharmaceutically acceptable salts, solvates, hydrates, primary metabolites and prodrugs thereof.

The invention provides compounds for use as medicaments, which act by inhibiting CYP17A1 and CYP19A1 enzymes. The compounds have particular application in the treatment of cancer especially prostate cancer and breast cancer. The compounds have the formula: [Chem. 1] wherein: R is independently selected from the group consisting of optionally substituted arylamide; optionally substituted alkylarylamide; optionally substituted aryl carboxamide; optionally substituted cyanopiperidine; optionally substituted oxopiperidine; optionally substituted N-(pyridin-3-yl); optionally substituted pyridin-3-yl; optionally substituted pyrazole-4-carboxamide; optionally substituted pyrimidin-4-ylcarboxamide; optionally substituted pyrimidin-4-ylcarboxamide; optionally substituted 1H-pyrrol-2-ylcarboxamide; optionally substituted morpholin carboxamide; optionally substituted 1H-indazol-3-ylcarboxamide; optionally substituted 5-cyanopiperidin-3-ylcarboxamide; optionally substituted quinolin-7-yl; optionally substituted pyrazin-2-ylcarboxamide; optionally substituted 1H-1,3-benzodiazole-6-carboxamide; and optionally substituted 3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-ylcarboxamide; Each R1, R2, R3, R4, R5 is independently selected from the group consisting of H; OH; a halogen atom; OCH.sub.3; and NH.sub.2; and X is independently selected from the group consisting of O, H and OH. Some of the compounds are claimed per se and the invention also encompasses pharmaceutically acceptable salts, solvates, hydrates, primary metabolites and prodrugs thereof.

Many microbes are capable of synthesizing anti-cancer products, however existing state of art is limited by focus on industrial production of the said products. A method and system for preparing a knowledgebase of microbes and microbial functions to identify good and bad microbes have been provided. The present disclosure therefore further describes methods and compositions for the risk assessment, prevention and management of various forms of cancer by using microbes, microbial products utilizing the knowledgebase of microbes and microbial function. The method is configured to priming the microbes inside the host for boosting the immune response against cancer initiation, progression, recurrence and associated side effects. The use of microbes and microbial products can be provided in the form of probiotics, supplements, and prebiotics etc. along with creation of right sets of nutrition conditions in the host for the proper functioning of the microbes and microbial products.

Bacterial plant pathogens such as Xanthomonas sp. and Pseudomonas syringae are developing resistance to various classes of antibiotics. A method and system for combating plant pathogenic bacterial infections have been provided. The system is configured to provide strategies to combat infections in plants caused by multi-drug resistant (MDR) plant pathogens. The strategy involves identifying potential target sites in the plant pathogen, which can be utilized to compromise its multiple virulence or essential functions at the same time. The idea used in this disclosure utilizes the fact that a conserved stretch of nucleotide sequence occurring multiple times on a pathogen genome in genomic neighborhood of genes encoding virulence factors or in vicinity of genes essential for pathogen survival encoded within the genome of the candidate pathogen can be targeted to disrupt the overall genetic machinery of the plant pathogen.

Bacterial plant pathogens such as Xanthomonas sp. and Pseudomonas syringae are developing resistance to various classes of antibiotics. A method and system for combating plant pathogenic bacterial infections have been provided. The system is configured to provide strategies to combat infections in plants caused by multi-drug resistant (MDR) plant pathogens. The strategy involves identifying potential target sites in the plant pathogen, which can be utilized to compromise its multiple virulence or essential functions at the same time. The idea used in this disclosure utilizes the fact that a conserved stretch of nucleotide sequence occurring multiple times on a pathogen genome in genomic neighborhood of genes encoding virulence factors or in vicinity of genes essential for pathogen survival encoded within the genome of the candidate pathogen can be targeted to disrupt the overall genetic machinery of the plant pathogen.

A method for controlling compression of data includes accessing genomic annotation data in one of a plurality of first file formats, extracting attributes from the genomic annotation data, dividing the genomic annotation data into multiple chunks, and processing the extracted attributes and chunks into correlated information. The method also includes selecting different compressors for the attributes and chunks identified in the correlated information and generating a file in a second file format that includes the correlated information and information indicative of the different compressors for the chunks and attributes indicated in the correlated information. The information indicative of the different compressors is processed into the second file format to allow selective decompression of the attributes and chunks indicated in correlated information.